People worldwide are living longer. According to WHO, one in six people in the world will be aged 60 years or over by 2030. However, aging increases vulnerability to a wide range of human disorders, including cancers, diabetes, cardiovascular diseases and neurodegenerative diseases. Roughly two-thirds of the 150,000 people who die each day globally suffer from age-associated diseases.

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has successfully established a unique approach to identify potential dual-purpose therapeutic targets of aging and age-associated diseases with PandaOmics, its proprietary AI-enabled biological target discovery platform.

Learn more (opens external site)

 

Leave a Reply

Submit a Team Connection

Click here to submit a new Bioinspired Design Connection (you must be logged in first).

Browse Team Connections

Choose by category, team or week:

BioDesign Connections by Category (2020 – 2022)

by Team (2022 only)

by Week (2022 only)

Most Recent Connections

Connection Interactions

Recent Comments

  1. to reduce the impact of car accidents, it may be possible to study the force diverting physics of cockroaches to…

Top Voted Connections